More on ROIV

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-111.8% Growth)
- Ratings (9.3 Score)

Upcoming Events

- Earnings (11/16/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Roivant Sciences (NQ:ROIV)
Delayed: 41.81 --0 (-0%)
Prev. Close $41.81  
Open$41.81 
52 Wk High$ 
52 Wk Low$ 
Day High$41.81 
Day Low$41.81 
P/E N/A  
EPS$ 
Volume4,983 

Friends, Peers and Foes (?): ROIVW, IMVT, ABUS, ABBV, AMGN (more...)

Sep 9, 2026 07:25 AM Roivant Sciences (ROIV) PT Raised to $47 at H.C. Wainwright
Sep 9, 2026 05:39 AM Roivant Sciences (ROIV) PT Raised to $46 at Guggenheim
Sep 9, 2026 05:38 AM Roivant Sciences (ROIV) PT Raised to $55 at TD Cowen
Sep 8, 2026 10:53 AM Roivant Sciences (ROIV) PT Raised to $52 at Jefferies
Sep 8, 2026 09:47 AM Roivant Sciences (ROIV) PT Raised to $55 at Piper Sandler
Sep 8, 2026 06:01 AM Roivant's mosliciguat shows PVR reduction in phase 2 PH-ILD trial
Sep 8, 2026 06:00 AM Pulmovant's mosliciguat hits primary endpoint in PH-ILD phase 2 trial
Sep 8, 2026 06:00 AM Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Stu
Sep 8, 2026 06:00 AM Pulmovant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier S
Sep 6, 2026 01:00 AM Pulmovant to present Phase 2 mosliciguat results at ERS Congress
View All Articles

Entities mentioned with ROIV

View All Entities